SCHEMBL14746241

SCHEMBL14746241

Fc1cccc(Nc2nc(-c3ccc(-c4ccccc4)cc3)cs2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.67
RAB9A P51151 13/20 0.67
MEN1 O00255 12/20 0.67
KMT2A Q03164 12/20 0.67
ATM Q13315 2/20 0.67
NPY5R Q15761 1/20 0.58
CASP3 P42574 3/20 0.54
SENP8 Q96LD8 3/20 0.54
SENP7 Q9BQF6 3/20 0.54
SENP6 Q9GZR1 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
NFKB1 P19838 1/20 0.53
MAPK1 P28482 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
CCR4 P51679 1/20 0.53
CYP1A1 P04798 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14742545 0.83 NPC1 (0.94) NPC1RAB9AMEN1KMT2AATM
SCHEMBL14746382 0.80 MEN1 (0.66) NPC1RAB9AMEN1KMT2AATM
SCHEMBL18029575 0.80 NPC1 (0.94) NPC1RAB9AMEN1KMT2AATM
SCHEMBL29427807 0.80 NPC1 (0.94) NPC1RAB9AMEN1KMT2AATM
SCHEMBL367354 0.79 GRM4 (0.68) NPC1RAB9AMEN1KMT2AATM
SCHEMBL14758492 0.78 NPC1 (0.77) NPC1RAB9AMEN1KMT2AATM
SCHEMBL24617426 0.78 MEN1 (0.60) NPC1RAB9AMEN1KMT2AATM
SCHEMBL29674606 0.78 MEN1 (0.60) NPC1RAB9AMEN1KMT2AATM
SCHEMBL1821894 0.77 ALOX5 (0.79) NPC1RAB9AMEN1KMT2ANPY5R
SCHEMBL12298090 0.77 CYP1A1 (0.83) NPC1RAB9AMEN1KMT2ANPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-06 US disclosed
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-06 US disclosed
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-06 US disclosed
WO-2013033037-A2 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-03-07 WO disclosed
WO-2013033037-A2 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS PRNP, PSEN1, PSEN2 NPC1 57/4885RAB9A 1779/4885MEN1 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.